The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Few details of the deal were disclosed in the announcement. A second liver biopsy will be performed after 18 months.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

SCIENMAG: Medicine & Health

DECEMBER 5, 2023

The UofL School of Nursing will use the funds from the Health Resources and Services Administration (HRSA) to develop and implement an accelerated Licensed Practical Nurse-to-Bachelor of Science in Nursing (LPN-to-BSN) pathway […] The University of Louisville has received $6.5

Nurses 87

Nurses Licensing Licensing Science 87

The Pharma Data

MARCH 9, 2022

Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets. About Novartis.

Licensing 52

Licensing Licensing Therapies Disease 52

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. star.edu.sg.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Target Review

SEPTEMBER 5, 2024

This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. Kristina is a pharmacist and holds a PhD in Medical Science from Linköping University.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

Drug Target Review

MARCH 4, 2025

Phenomix Sciences , led by CEO Mark Bagnall, is using precision medicine to make treatments more targeted and effective. Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach. Meet Mark Bagnall Mark Bagnall currently serves as CEO of Phenomix Sciences, Inc.

Therapies 52

Therapies Treatment Clinical Trials Science 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc.

Licensing 52

Licensing Licensing Vaccine FDA 52

Drug Target Review

OCTOBER 14, 2024

About the authors Dr Raminderpal Singh Dr Raminderpal Singh is a recognised visionary in the implementation of AI across technology and science-focused industries. Neil is a scientific business leader with thirty years’ experience of the pharmaceutical, biotechnology and life sciences investment industries.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

Drug Channels

OCTOBER 19, 2020

16th Annual Life Sciences Trade and Channel Strategies. December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel. Get ready to hit the ground running in 2021 by closing out the year at Trade and Channel 2020 ! Download the agenda to plan your sessions and wrap up your week armed with critical updates and valuable takeaways.

Science 52

Science Specialty Pharmacies Pharmacy Licensing 52

Drug Target Review

AUGUST 9, 2024

The science behind drug formulation The formulation of a drug is both an art and a science, requiring a deep understanding of the drug’s chemical and physical properties. Inhalers are useful in respiratory conditions, whereas topical treatments can be applied directly to the skin for localised treatment.

Science 59

Science Drugs Compliance Drug Development 59

The Pharma Data

NOVEMBER 15, 2020

” “We are committed to advancing innovative science and transformative medicines for people affected by different immune mediated diseases”, says James Sabry , Global Head, Roche Pharma Partnering. Lead Pharma is headquartered at Pivot Park, the biopharmaceutical life sciences campus in Oss, the Netherlands.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

JANUARY 31, 2021

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. About Gilead Sciences. Gilead Sciences, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

OCTOBER 27, 2020

VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / (CSE:OVAT) – Ovation Science Inc. (“Ovation” or the “Company”) is pleased to announce that its DermSafe® Hand Sanitizer Lotion is listed on Amazon.ca. DermSafe is a pharmaceutical-grade hand sanitizer lotion made without alcohol and backed by science.

Science 52

Science Production Pharmaceuticals Licensing 52

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. About Pfizer: Breakthroughs That Change Patients’ Lives.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

Broad Institute

MAY 14, 2024

“His work really illustrates that sometimes a remarkable technology can emerge not only from people trying to build technologies but from someone who is trying to use basic science to understand a fascinating biological phenomenon,” said Varmus. coli genome and let the E. and around the world. “I

RNA 84

RNA Production Molecular Biology Laboratories 84

The Pharma Data

JUNE 14, 2023

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer. Financial details have not been disclosed.

Licensing 40

Licensing Licensing Small Molecule Science 40

The Pharma Data

DECEMBER 23, 2020

24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences Inc. On December 18, 2020 – The Company issued the following press release: “Tauriga Sciences Inc. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. Contact: Tauriga Sciences, Inc. NEW YORK, NY, Dec. 62/990,709.

Science 52

Science Pharmaceuticals Clinical Development Production 52

The Pharma Data

MAY 6, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

Agency IQ

JUNE 2, 2023

What we expect to be talking about in June: Supply chain information: Under the FDORA legislation, holders of Biologics License Applications are required to submit a one-time report to the FDA on June 25, 2023 regarding which of their biologic products are available for sale or have been withdrawn from the market.

FDA 52

FDA Science Licensing Licensing 52

Drug Target Review

NOVEMBER 25, 2024

I started my career with a degree in biomedical sciences from the University of East Anglia in Norwich, UK. Personally, I went from working in licensing and business development in big pharma straight to being a CEO. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 26, 2020

27, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences Inc. ABOUT TAURIGA SCIENCES INC. . Tauriga Sciences, Inc. TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. Tauriga Sciences, Inc. NEW YORK, NY, Nov.

Science 52

Science Production Licensing Licensing 52

The Pharma Data

SEPTEMBER 29, 2020

Mechanisms for rapidly escalating supply must be aligned with the specific context of a rapid pandemic response and tailored to each product, with options including early voluntary licensing and appropriate approaches to peer-to-peer innovator company manufacturing agreements. . Enable affordability for lower income countries.

Science 52

Science Vaccine Production Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. About AstraZeneca.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

MARCH 25, 2022

Food and Drug Administration (FDA) has extended the review of the supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion-dependent (NTD) beta thalassemia to June 27, 2022. Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. in November 2021.

Licensing 52

Licensing Licensing Drugs Treatment 52

SCIENMAG: Medicine & Health

JUNE 9, 2023

Virginia Tech Intellectual Properties (VTIP) with LINK + LICENSE + LAUNCH’s Proof-of-Concept Program has provided the springboard for faculty to bring their research to market. Over the past four years, the program has funded 24 Virginia Tech research projects. Credit: Photo by Luke Hayes for Virginia Tech.

Research 84

Research Licensing Licensing Marketing 84

Drug Target Review

JULY 6, 2023

3 Furthermore, the act “removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.” A new research paper, co-authored by PETA Science Consortium International e.V., Toxicological Sciences. 2022;119(41).

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

The Pharma Data

SEPTEMBER 28, 2021

After manufacturers analyze their clinical test data, they’re going to compile the knowledge and should request an emergency use authorization (EUA) or submit for approval a biologics license application (BLA), as appropriate, for this young population to the FDA. we’ve to let the science and data guide us.

Vaccine 52

Vaccine FDA Science Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. About Burning Rock.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

JUNE 7, 2022

Nasdaq: BIIB) — Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinson’s disease (PD). Biogen Inc.

Licensing 40

Licensing Licensing Small Molecule Disease 40

Drug Hunter

APRIL 20, 2023

3: YCT529 (University of Minnesota, Georg lab, licensed by YourChoice Therapeutics, 13%) In third place was YCT529 , from UMN/YourChoice Therapeutics. A recent preclinical study demonstrated that MRTX113 was able to reduce tumor size in KPC mice , a pancreatic cancer model that is resistant to every drug tested.

Small Molecule 130

Small Molecule Clinical Trials Trials Licensing 130

Molecule Blog

JANUARY 9, 2023

IP-NFTs and Decentralized, Autonomous Science Today, most science is conducted at centralized institutions with a high barrier to entry and a reliance on imprecise human labor. Research is built on data (and sometimes code) that routinely isn’t shared, affecting our ability to replicate science.

Research 52

Research Licensing Licensing Science 52

Fierce BioTech

DECEMBER 13, 2023

7 “Make or Break” Factors for Emerging Biopharma Companies This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.

Licensing 52

Licensing Licensing Science Production 52

Perficient: Drug Development

SEPTEMBER 19, 2023

More information will be available in the coming weeks. Expanded Partnerships Google Salesforce and Google are expanding their partnership to further integrate their products.

Licensing 59

Licensing Licensing Production Marketing 59

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. Gilead Sciences, Inc. About Gilead Sciences. Gilead Sciences, Inc.

Licensing 52

Licensing Licensing Research Protein Expression 52

Drug Target Review

SEPTEMBER 7, 2023

A patent lawyer by training, Keir represented companies of various sizes in all stages of transactions, including licensing and M&A.

Treatment 98

Treatment Licensing Licensing Disease 98